Navigation Links
Verenium Announces Debt Repurchase
Date:7/28/2011

SAN DIEGO, July 28, 2011 /PRNewswire/ -- Verenium Corporation (NASDAQ: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced that it repurchased approximately $5.2 million in principal amount of its 5.5% Notes and approximately $3 million in principal amount of 9% Notes.  

"We are very pleased to have taken another important step toward creating a capital structure that is appropriate to support the continued growth and success of the Company," said Jeffrey Black, Senior Vice President and Chief Financial Officer at Verenium.  

In total, the Company repurchased approximately $8.2 million in principal amount of its 5.5% and 9% Notes, leaving an aggregate of $36 million in principal amount of 5.5% and 9% Notes outstanding. To effect this repurchase, the Company paid a total of $7.7 million in cash to a single institutional investor, excluding accrued interest, as of the closing date.

About Verenium

Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actua
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Announces Signing of Lease for New Office and Lab Space
2. Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes
3. Verenium Receives CLARUS Award at MDB Capitals Bright Lights Conference 2011
4. Verenium to Present at Upcoming Conferences
5. Verenium to Speak at the 2011 BIO World Congress on Industrial Biotechnology and Bioprocessing
6. Verenium to Present at MDB Capital Groups Bright Lights Conference
7. Verenium Announces Debt Repurchase
8. Worlds Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Vereniums Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval
9. Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results
10. Verenium to Present at Jefferies 11th Global Clean Technology Conference
11. Verenium Announces Favorable Outcome of Capital Ventures International Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... TORONTO , Feb. 26, 2015 /PRNewswire/ - SQI ... SQIDF), a life sciences company that develops and commercializes ... reported its financial and operational results for the fiscal ... this press release are in Canadian dollars (CAD), unless ... Company continued to win new business from our existing ...
(Date:2/26/2015)... , Feb. 26, 2015 Protiviti ( www.protiviti.com ... version of the Governance Portal , designed to ... and compliance (GRC) tasks across multiple business units and ... to help customers better align their controls with the ... Commission ) requirements. In response to client feedback, Protiviti ...
(Date:2/26/2015)... 26, 2015 On behalf of biotech ... companies, Wilentz, Goldman & Spitzer, P.A. (Wilentz) ... lawsuit against Genewiz Inc. in excess of $10 million. ... GenScript’s trade secrets, and that it improperly hired one ... an order denying motions for judgment notwithstanding the verdict, ...
(Date:2/26/2015)... , Feb. 26, 2015 BioEnterprise today announced ... have attracted more than $2 billion in growth funding ... and national investors, strategic sources, state – including the ... of the $2 billion has been raised in the ... on the heels of the BioEnterprise Midwest Healthcare ...
Breaking Biology Technology:SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4
... (Nasdaq: OPTR ) today announced its financial results for ... loss for the first quarter of 2009 of $10.9 million, or ... This compares to a net loss for the first quarter ... and development expenses in the first quarter of 2009 were $8.8 ...
... NOTTINGHAM, UK, May 7 Human Genome Sciences, ... Biopharma, a part of Novozymes (Nasdaq: NZYM B), ... license agreement to allow both companies to expand ... http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )Under the amended ...
... Molecular,Therapeutics (Euronext: AMT), a leader in the field ... the first patient in a preregistration,clinical trial with ... (LPLD), a seriously debilitating and,potentially lethal disease. , ... has been designed to gather additional,data on the ...
Cached Biology Technology:Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 2Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 3Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 4Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 5Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement 2Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement 3Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement 4AMT Starts Preregistration Trial for Glybera(TM) 2AMT Starts Preregistration Trial for Glybera(TM) 3
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric ... recent success of the Wocket™ smart wallet at CES 2015 in ... named as one of the "11 Hot Products at CES" in a ... CES So Far" by Newseveryday.com and "The top 10 gadgets from CES ...
(Date:1/22/2015)... 22, 2015 , Europe,s ... The European Patent Office to present a video retrospective of ... to be featured: Christofer Toumazou and Sophie Wilson ... and winners of the Award   Starting on 22 ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... rhinovirus (HRV), the leading cause of most common colds, ... respiratory failure, graft dysfunction and death. The two were ... suffered clinically significant respiratory infection from HRV in both ... that HRV affects only upper airway tissue. , The ...
... chemical dopamine has been thought of as the brain's "pleasure ... rewards a person or animal for one activity or another. ... and heroin amplify this effect ?an action that may lie ... new study from the University of Michigan adds a new ...
... Alberta in Edmonton, Canada have been able to put a ... defies classification. , The findings, published recently in the Journal ... the creature, named Horolodectes sunae, for the unusual shape of ... years ago, soon after the dinosaurs went extinct, in a ...
Cached Biology News:Common cold virus leads to death in lung transplant patients 2Pleasure and pain: Study shows brain's 'pleasure chemical' is involved in response to pain too 2Pleasure and pain: Study shows brain's 'pleasure chemical' is involved in response to pain too 3Pleasure and pain: Study shows brain's 'pleasure chemical' is involved in response to pain too 4Researchers give name to ancient mystery creature 2
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Mouse monoclonal [YPF19] to Yersinia pestis F1 antigen ( Abpromise for all tested applications)....
... This CLS number is a ... match Cornings product number. If showing ... the old Sigma-Aldrich number (E6152) or ... Comp Dim: H diam. 11.25 ...
... gradient system uses three Adept CE 4100 ... a flow rate in one microlitre increaments. ... scanning detector, provides added flexibility. The ... a photodiode array detection and provides superior ...
Biology Products: